French Public Health Code
In forceThe following biological analyses and screening tests are carried out for each donation of blood or blood components intended for the preparation of labile blood products for direct therapeutic use:
1° Erythrocyte blood grouping, which includes :
a) Determination of ABO and Rh(D) groups, also known as Rh 1 (RH1) ;
b) Determining the Rh phenotype: C(RH2), E(RH3), c(RH4) and e(RH5) and Kell(KEL1) for the first two donations;
2° Testing for anti-erythrocyte antibodies that may have a clinical impact on transfusion;
3° Detection of anti-A and anti-B immune antibodies for donations intended for the preparation of the following labile blood products:
a) Platelet concentrates from apheresis ;
b) Whole blood ;
c) Granulocyte concentrates from apheresis;
d) Plasma intended for the preparation of mixtures of granulocyte concentrates from whole blood.
4° Haemoglobin assay;
5° The following biological tests and analyses with a view to screening for transmissible diseases:
a) Serological screening for syphilis ;
b) Detection of HBs antigen ;
c) Detection of anti-HIV 1 and anti-HIV 2 antibodies;
d) Detection of anti-HCV antibodies;
e) Detection of anti-HTLV-I and anti-HTLV-II antibodies for products taken from first-time donors and in the departments of Guadeloupe and Martinique;
f) Detection of anti-malarial antibodies under the conditions laid down by the decree provided for in Article R. 1221-5;
g) Detection of anti-HBc antibodies;
h) Detection of the viral genome of the HIV-1 and HCV viruses;
i) Detection of anti-Trypanosoma cruzi antibodies under the conditions laid down by the decree provided for in article R. 1221-5.
